ADC Biotechnology

ADC Biotechnology is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.

With surging numbers of “second generation” drugs in development, tumour-selective ADCs are building a significant position in the oncology field – the fastest growing sector in healthcare.

ADC Bio’s technology aims to become a new paradigm in the way ADCs are developed and manufactured, increasing accessibility for patients by helping to contain ADC production complexity and cost. The patented Lock – Release technology results in fast, simple and robust conjugation processes, with the potential to eliminate several process steps whilst enhancing product quality.

ADC Bio brings knowledge, experience and technical differentiation to the rapid growth ADC sector and is an ideal partner for basic research, development, scale-up and commercialisation challenges.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.